Download PDF
Semin Respir Crit Care Med 2016; 37(05): 783-796
DOI: 10.1055/s-0036-1592116
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Small Cell Lung Cancer

Gregory P. Kalemkerian
1   Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
12 October 2016 (online)

    Permissions and Reprints

Abstract

Small cell lung cancer (SCLC) is a high-grade neuroendocrine tumor characterized by rapid growth, early metastatic spread, and initial responsiveness to therapy. Although the incidence of SCLC is declining, it remains one of the common causes of cancer-related mortality. Initial evaluation of patients with SCLC should focus on determining the extent of disease and the ability of the patient to tolerate specific therapy. Positron emission tomography (PET) can improve the accuracy of staging and treatment planning in many patients. Limited-stage (LS) SCLC is a potentially curable disease with long-term survival of 20 to 25% when treated with platinum-based chemotherapy plus concurrent thoracic radiation. Hyperfractionated (twice daily) thoracic radiation and prophylactic cranial irradiation (PCI) may improve survival in selected patients with LS-SCLC. For patients with extensive-stage (ES) SCLC, combination chemotherapy prolongs survival and improves quality of life, but long-term survival is rare. The use of PCI and sequential thoracic radiation has been reported to improve survival in selected patients with ES-SCLC. Many chemotherapeutic drugs have activity in SCLC, but little progress has been made in the systemic treatment of SCLC in almost three decades. Although many potential molecular targets have been identified in the preclinical studies of SCLC, molecularly targeted therapy has yet to demonstrate consistent clinical activity. Nevertheless, future advances in SCLC will depend on the development of rational therapeutic strategies which target the molecular mechanisms that drive cellular proliferation, survival, and immunological avoidance.

Keywords

small cell lung carcinoma - lung cancer - incidence - cancer staging - positron emission tomography - chemotherapy - radiotherapy - immunotherapy
 

  • References

  • 1 Pesch B, Kendzia B, Gustavsson P , et al. Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 2012; 131 (5) 1210-1219
    CrossrefPubMedGoogle Scholar
  • 2 Churg A. Lung cancer cell type and occupational exposure. In: Samet JM, , ed. Epidemiology of Lung Cancer. Marcel Dekker: New York; 1994: 413-436
    Google Scholar
  • 3 Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the National Surveillance, Epidemiology, and End-Results database. J Clin Oncol 2006; 24 (18S): 384s [abstract 7082]
    PubMedGoogle Scholar
  • 4 Govindan R, Page N, Morgensztern D , et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24 (28) 4539-4544
    CrossrefPubMedGoogle Scholar
  • 5 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65 (1) 5-29
    CrossrefPubMedGoogle Scholar
  • 6 Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973; 4 (2) 31-42
    PubMedGoogle Scholar
  • 7 Stahel RA, Ginsberg R, Havemann K , et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989; 5: 119-126
    CrossrefPubMedGoogle Scholar
  • 8 Micke P, Faldum A, Metz T , et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?. Lung Cancer 2002; 37 (3) 271-276
    CrossrefPubMedGoogle Scholar
  • 9 American Joint Committee on Cancer. AJCC Cancer Staging Handbook, 7th ed. New York: Springer; 2010: 299-323
    Google Scholar
  • 10 Shepherd FA, Crowley J, Van Houtte P , et al. The IASLC Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007; 2: 1067-1077
    CrossrefPubMedGoogle Scholar
  • 11 Goldstraw P, Crowley J, Chansky K , et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2 (8) 706-714
    CrossrefPubMedGoogle Scholar
  • 12 Vallières E, Shepherd FA, Crowley J , et al; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4 (9) 1049-1059
    CrossrefPubMedGoogle Scholar
  • 13 Ignatius Ou SH, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol 2009; 4 (3) 300-310
    CrossrefPubMedGoogle Scholar
  • 14 Hochstenbag MM, Twijnstra A, Wilmink JT, Wouters EF, ten Velde GP. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol 2000; 48 (3) 243-248
    CrossrefPubMedGoogle Scholar
  • 15 Seute T, Leffers P, Wilmink JT, ten Velde GP, Twijnstra A. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006; 24 (13) 2079-2083
    CrossrefPubMedGoogle Scholar
  • 16 Campling B, Quirt I, DeBoer G, Feld R, Shepherd FA, Evans WK. Is bone marrow examination in small-cell lung cancer really necessary?. Ann Intern Med 1986; 105 (4) 508-512
    CrossrefPubMedGoogle Scholar
  • 17 Tritz DB, Doll DC, Ringenberg QS , et al. Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables. Cancer 1989; 63 (4) 763-766
    CrossrefPubMedGoogle Scholar
  • 18 Levitan N, Byrne RE, Bromer RH , et al. The value of the bone scan and bone marrow biopsy staging small cell lung cancer. Cancer 1985; 56 (3) 652-654
    CrossrefPubMedGoogle Scholar
  • 19 Kalemkerian GP, Loo BW, Akerley W , et al. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer, version 1. 2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
    PubMedGoogle Scholar
  • 20 Hauber HP, Bohuslavizki KH, Lund CH, Fritscher-Ravens A, Meyer A, Pforte A. Positron emission tomography in the staging of small-cell lung cancer : a preliminary study. Chest 2001; 119 (3) 950-954
    CrossrefPubMedGoogle Scholar
  • 21 Schumacher T, Brink I, Mix M , et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001; 28 (4) 483-488
    CrossrefPubMedGoogle Scholar
  • 22 Shen YY, Shiau YC, Wang JJ, Ho ST, Kao CH. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 2002; 22 (2B) 1257-1264
    PubMedGoogle Scholar
  • 23 Chin Jr R, McCain TW, Miller AA , et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002; 37 (1) 1-6
    PubMedGoogle Scholar
  • 24 Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003; 44 (12) 1911-1917
    PubMedGoogle Scholar
  • 25 Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004; 22 (16) 3248-3254
    CrossrefPubMedGoogle Scholar
  • 26 Brink I, Schumacher T, Mix M , et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31 (12) 1614-1620
    CrossrefPubMedGoogle Scholar
  • 27 Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol 2004; 27 (2) 164-171
    CrossrefPubMedGoogle Scholar
  • 28 Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007; 30 (1) 45-50
    CrossrefPubMedGoogle Scholar
  • 29 Fischer BM, Mortensen J, Langer SW , et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007; 18 (2) 338-345
    CrossrefPubMedGoogle Scholar
  • 30 Niho S, Fujii H, Murakami K , et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007; 57 (3) 328-333
    CrossrefPubMedGoogle Scholar
  • 31 Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS. Can positron emission tomography be used as a staging tool for small-cell lung cancer?. Clin Lung Cancer 2008; 9 (1) 30-34
    CrossrefPubMedGoogle Scholar
  • 32 Azad A, Chionh F, Scott AM , et al. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol 2010; 12 (4) 443-451
    CrossrefPubMedGoogle Scholar
  • 33 Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer. Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013; 143 (5 Suppl): e400S-e419S
    CrossrefPubMedGoogle Scholar
  • 34 Ruben JD, Ball DL. The efficacy of PET staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. J Thorac Oncol 2012; 7 (6) 1015-1020
    CrossrefPubMedGoogle Scholar
  • 35 Lu YY, Chen JH, Liang JA, Chu S, Lin WY, Kao CH. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nucl Med Commun 2014; 35 (7) 697-703
    CrossrefPubMedGoogle Scholar
  • 36 van Loon J, De Ruysscher D, Wanders R , et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010; 77 (2) 329-336
    CrossrefPubMedGoogle Scholar
  • 37 Hillner BE, Siegel BA, Shields AF , et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 2008; 49 (12) 1928-1935
    CrossrefPubMedGoogle Scholar
  • 38 Xanthopoulos EP, Corradetti MN, Mitra N , et al. Impact of PET staging in limited-stage small-cell lung cancer. J Thorac Oncol 2013; 8 (7) 899-905
    CrossrefPubMedGoogle Scholar
  • 39 Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10 (6) 890-895
    CrossrefPubMedGoogle Scholar
  • 40 Pignon JP, Arriagada R, Ihde DC , et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327 (23) 1618-1624
    CrossrefPubMedGoogle Scholar
  • 41 Fried DB, Morris DE, Poole C , et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004; 22 (23) 4837-4845
    CrossrefPubMedGoogle Scholar
  • 42 De Ruysscher D, Pijls-Johannesma M, Bentzen SM , et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24 (7) 1057-1063
    CrossrefPubMedGoogle Scholar
  • 43 Turrisi III AT, Kim K, Blum R , et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340 (4) 265-271
    CrossrefPubMedGoogle Scholar
  • 44 Bonner JA, Sloan JA, Shanahan TG , et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999; 17 (9) 2681-2691
    CrossrefPubMedGoogle Scholar
  • 45 Jeremic B, Shibamoto Y, Nikolic N , et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol 1999; 17 (7) 2092-2099
    CrossrefPubMedGoogle Scholar
  • 46 Slotman BJ, van Tinteren H, Praag JO , et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385 (9962) 36-42
    CrossrefPubMedGoogle Scholar
  • 47 Aupérin A, Arriagada R, Pignon JP , et al; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341 (7) 476-484
    CrossrefPubMedGoogle Scholar
  • 48 Slotman B, Faivre-Finn C, Kramer G , et al; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357 (7) 664-672
    CrossrefPubMedGoogle Scholar
  • 49 Slotman BJ, Mauer ME, Bottomley A , et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009; 27 (1) 78-84
    CrossrefPubMedGoogle Scholar
  • 50 Seto T, Takahashi T, Yamanaka T , et al. Prophylactic cranial irradiation has a detrimental effect on the overall survival of patients with extensive disease small cell lung cancer: results of a Japanese randomized phase III trial. J Clin Oncol 2014; 32 (15S): [abstract 7503]
    PubMedGoogle Scholar
  • 51 Greco FA, Oldham RK. Clinical management of patients with small cell lung cancer. In: Greco FA, Oldham RK, Bunn PA, , eds. Small Cell Lung Cancer. New York: Grune & Stratton; 1981: 353-379
    Google Scholar
  • 52 Lowenbraun S, Bartolucci A, Smalley RV, Lynn M, Krauss S, Durant JR. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 1979; 44 (2) 406-413
    CrossrefPubMedGoogle Scholar
  • 53 Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327 (20) 1434-1441
    CrossrefPubMedGoogle Scholar
  • 54 Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985; 3 (11) 1471-1477
    PubMedGoogle Scholar
  • 55 Fukuoka M, Furuse K, Saijo N , et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83 (12) 855-861
    CrossrefPubMedGoogle Scholar
  • 56 Roth BJ, Johnson DH, Einhorn LH , et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10 (2) 282-291
    CrossrefPubMedGoogle Scholar
  • 57 Sundstrøm S, Bremnes RM, Kaasa S , et al; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20 (24) 4665-4672
    CrossrefPubMedGoogle Scholar
  • 58 Pujol JL, Carestia L, Daurès JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83 (1) 8-15
    CrossrefPubMedGoogle Scholar
  • 59 Mascaux C, Paesmans M, Berghmans T , et al; European Lung Cancer Working Party (ELCWP). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30 (1) 23-36
    CrossrefPubMedGoogle Scholar
  • 60 Noda K, Nishiwaki Y, Kawahara M , et al; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346 (2) 85-91
    CrossrefPubMedGoogle Scholar
  • 61 Hanna N, Bunn Jr PA, Langer C , et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24 (13) 2038-2043
    CrossrefPubMedGoogle Scholar
  • 62 Lara Jr PN, Natale R, Crowley J , et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27 (15) 2530-2535
    CrossrefPubMedGoogle Scholar
  • 63 Zatloukal P, Cardenal F, Szczesna A , et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010; 21 (9) 1810-1816
    CrossrefPubMedGoogle Scholar
  • 64 Kubota K, Hida T, Ishikura S , et al; Japan Clinical Oncology Group. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol 2014; 15 (1) 106-113
    CrossrefPubMedGoogle Scholar
  • 65 Hermes A, Bergman B, Bremnes R , et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008; 26 (26) 4261-4267
    CrossrefPubMedGoogle Scholar
  • 66 Schmittel A, Fischer von Weikersthal L, Sebastian M , et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006; 17 (4) 663-667
    CrossrefPubMedGoogle Scholar
  • 67 Eckardt JR, von Pawel J, Papai Z , et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006; 24 (13) 2044-2051
    CrossrefPubMedGoogle Scholar
  • 68 Fink TH, Huber RM, Heigener DF , et al; “Aktion Bronchialkarzinom” (ABC Study Group). Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol 2012; 7 (9) 1432-1439
    CrossrefPubMedGoogle Scholar
  • 69 Jiang J, Liang X, Zhou X , et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010; 5 (6) 867-873
    CrossrefPubMedGoogle Scholar
  • 70 Lima JP, dos Santos LV, Sasse EC, Lima CS, Sasse AD. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol 2010; 5 (12) 1986-1993
    CrossrefPubMedGoogle Scholar
  • 71 Thomas P, Castelnau O, Paillotin D , et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study. J Clin Oncol 2001; 19 (5) 1320-1325
    CrossrefPubMedGoogle Scholar
  • 72 Lyss AP, Herndon II JE, Lynch Jr TJ , et al. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer 2002; 3 (3) 205-210 , discussion 211–212
    CrossrefPubMedGoogle Scholar
  • 73 Leyvraz S, Pampallona S, Martinelli G , et al; Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 2008; 100 (8) 533-541
    CrossrefPubMedGoogle Scholar
  • 74 Lorigan P, Woll PJ, O'Brien MER, Ashcroft LF, Sampson MR, Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005; 97 (9) 666-674
    CrossrefPubMedGoogle Scholar
  • 75 Furuse K, Fukuoka M, Nishiwaki Y , et al; The Japan Clinical Oncology Group. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. J Clin Oncol 1998; 16 (6) 2126-2132
    CrossrefPubMedGoogle Scholar
  • 76 Niell HB, Herndon II JE, Miller AA , et al; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005; 23 (16) 3752-3759
    CrossrefPubMedGoogle Scholar
  • 77 Elias A, Ibrahim J, Skarin AT , et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999; 17 (4) 1175-1184
    CrossrefPubMedGoogle Scholar
  • 78 Rossi A, Garassino MC, Cinquini M , et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010; 70 (2) 119-128
    CrossrefPubMedGoogle Scholar
  • 79 Schiller JH, Adak S, Cella D, DeVore III RF, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19 (8) 2114-2122
    CrossrefPubMedGoogle Scholar
  • 80 Hanna NH, Einhorn LH. Small-cell lung cancer: state of the art. Clin Lung Cancer 2002; 4 (2) 87-94
    CrossrefPubMedGoogle Scholar
  • 81 Skarlos DV, Samantas E, Kosmidis P , et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5 (7) 601-607
    CrossrefPubMedGoogle Scholar
  • 82 Rossi A, Di Maio M, Chiodini P , et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012; 30 (14) 1692-1698
    CrossrefPubMedGoogle Scholar
  • 83 Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987; 23 (9) 1409-1411
    CrossrefPubMedGoogle Scholar
  • 84 Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987; 23 (11) 1697-1699
    CrossrefPubMedGoogle Scholar
  • 85 O'Brien MER, Ciuleanu TE, Tsekov H , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24 (34) 5441-5447
    CrossrefPubMedGoogle Scholar
  • 86 von Pawel J, Schiller JH, Shepherd FA , et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17 (2) 658-667
    CrossrefPubMedGoogle Scholar
  • 87 Pietanza MC, Kadota K, Huberman K , et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012; 18 (4) 1138-1145
    CrossrefPubMedGoogle Scholar
  • 88 Zauderer MG, Drilon A, Kadota K , et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer 2014; 86 (2) 237-240
    CrossrefPubMedGoogle Scholar
  • 89 Schmittel A, Knödler M, Hortig P, Schulze K, Thiel E, Keilholz U. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007; 55 (1) 109-113
    CrossrefPubMedGoogle Scholar
  • 90 Lammers PE, Shyr Y, Li CI , et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol 2014; 9 (4) 559-562
    CrossrefPubMedGoogle Scholar
  • 91 Yana T, Negoro S, Takada M , et al; West Japan Thoracic Oncology Group. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007; 25 (3) 253-258
    CrossrefPubMedGoogle Scholar
  • 92 Onoda S, Masuda N, Seto T , et al; Thoracic Oncology Research Group Study 0301. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006; 24 (34) 5448-5453
    CrossrefPubMedGoogle Scholar
  • 93 Igawa S, Yamamoto N, Ueda S , et al. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol 2007; 2 (8) 741-744
    CrossrefPubMedGoogle Scholar
  • 94 Ettinger DS, Jotte R, Lorigan P , et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010; 28 (15) 2598-2603
    CrossrefPubMedGoogle Scholar
  • 95 Satouchi M, Kotani Y, Shibata T , et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol 2014; 32 (12) 1262-1268
    CrossrefPubMedGoogle Scholar
  • 96 Inoue A, Sugawara S, Yamazaki K , et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008; 26 (33) 5401-5406
    CrossrefPubMedGoogle Scholar
  • 97 Jotte R, Conkling P, Reynolds C , et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011; 29 (3) 287-293
    CrossrefPubMedGoogle Scholar
  • 98 von Pawel J, Jotte R, Spigel DR , et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014; 32 (35) 4012-4019
    CrossrefPubMedGoogle Scholar
  • 99 Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, Angeletti CA. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 2002; 21 (6) 1105-1110
    CrossrefPubMedGoogle Scholar
  • 100 Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998; 79 (2) 144-146
    CrossrefPubMedGoogle Scholar
  • 101 Horn L, Dahlberg SE, Sandler AB , et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009; 27 (35) 6006-6011
    CrossrefPubMedGoogle Scholar
  • 102 Spigel DR, Townley PM, Waterhouse DM , et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011; 29 (16) 2215-2222
    CrossrefPubMedGoogle Scholar
  • 103 Ready NE, Dudek AZ, Pang HH , et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011; 29 (33) 4436-4441
    CrossrefPubMedGoogle Scholar
  • 104 Spigel DR, Hainsworth JD, Yardley DA , et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28 (1) 43-48
    CrossrefPubMedGoogle Scholar
  • 105 Ready NE, Pang HH, Gu L , et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study – CALGB 30504 (Alliance). J Clin Oncol 2015; 33 (15) 1660-1665
    CrossrefPubMedGoogle Scholar
  • 106 Arnold AM, Seymour L, Smylie M , et al; National Cancer Institute of Canada Clinical Trials Group Study BR.20. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25 (27) 4278-4284
    CrossrefPubMedGoogle Scholar
  • 107 Rudin CM, Hann CL, Peacock CD, Watkins DN. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw 2008; 6 (3) 315-322
    PubMedGoogle Scholar
  • 108 Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes?. Clin Cancer Res 2015; 21 (10) 2244-2255
    CrossrefPubMedGoogle Scholar
  • 109 Schneider BJ, Kalemkerian GP. Personalized therapy of small cell lung cancer. In: Ahmad A, Gadgeel SM, , eds. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. New York: Springer; 2016: 149-174
    CrossrefGoogle Scholar
  • 110 Pietanza MC, Spigel D, Bauer TM , et al. Safety, activity and response durability assessment of single-agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate, in small cell lung cancer. European Cancer Congress; 2015. , Abstract 7LBA
    Google Scholar
  • 111 Peifer M, Fernández-Cuesta L, Sos ML , et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44 (10) 1104-1110
    CrossrefPubMedGoogle Scholar
  • 112 Rudin CM, Durinck S, Stawiski EW , et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012; 44 (10) 1111-1116
    CrossrefPubMedGoogle Scholar
  • 113 George J, Lim JS, Jang SJ , et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524 (7563) 47-53
    CrossrefPubMedGoogle Scholar
  • 114 Byers LA, Wang J, Nilsson MB , et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2 (9) 798-811
    CrossrefPubMedGoogle Scholar
  • 115 Sos ML, Dietlein F, Peifer M , et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A 2012; 109 (42) 17034-17039
    CrossrefPubMedGoogle Scholar
  • 116 Reck M, Bondarenko I, Luft A , et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24 (1) 75-83
    CrossrefPubMedGoogle Scholar
  • 117 Ott PA, Fernandez MEE, Hiret S , et al. Pembrolizumab (MK-3475) in patients with extensive-stage small cell lung cancer: Preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol 2015; 33 (15S): 400s [ abstract 7502]
    PubMedGoogle Scholar
  • 118 Antonia SJ, Bendell JC, Taylor MH , et al. Phase I/II study of nivolumab with or without ipilumumab for treatment of recurrent small cell lung cancer: CA209–032. J Clin Oncol 2015; 33 (15S): 400s [ abstract 7503]
    PubMedGoogle Scholar
  • 119 Hou JM, Krebs MG, Lancashire L , et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012; 30 (5) 525-532
    CrossrefPubMedGoogle Scholar